119. Gynecol Obstet Fertil Senol. 2018 Jun;46(6):509-513. doi:10.1016/j.gofs.2018.05.002.[Risk of axillary recurrence after sentinel lymph node biopsy before neoadjuvant chemotherapy in breast cancer].[Article in French]Tardieu A(1), Mesnard C(2), Margueritte F(2), Mollard J(2), Lacorre A(2), Aubard Y(2), Deluche E(3), Gauthier T(4).Author information: (1)Département de gynécologie-obstétrique, hôpital Mère-Enfant, CHU de Limoges,avenue Dominique-Larrey, 87000 Limoges, France. Electronic address:antoine.tardieu@hotmail.fr.(2)Département de gynécologie-obstétrique, hôpital Mère-Enfant, CHU de Limoges,avenue Dominique-Larrey, 87000 Limoges, France.(3)Département d'oncologie médicale, CHU de Limoges, avenue Dominique-Larrey,87000 Limoges, France.(4)Département de gynécologie-obstétrique, hôpital Mère-Enfant, CHU de Limoges,avenue Dominique-Larrey, 87000 Limoges, France; UMR-1248, faculté de médecine,rue du docteur-Marcland, 87000 Limoges, France.OBJECTIVES: In case of large breast cancer, neoadjuvant chemotherapy (NAC) can beperformed to reduce the size of the tumor and thus perform a conservativesurgery. The place of the sentinel lymph node biopsy (SLNB) in case of NAC isstill debated. The main aim of this study is to assess the risk of axillaryrecurrence after negative SLNB before NAC.METHODS: It is a retrospective, observational and uni-centric study. We included 18 to 80-year-old patients with unilateral breast cancer requiring a NAC and witha negative SLNB before NAC. Our primary endpoint was axillary recurrence.RESULTS: Between August 2006 and October 2016, 64 patients had a negative GSperforming before a NAC and did not benefit from axillary dissection after NAC.The average duration of follow-up was 37 months. During our follow-up, we did notfind any cases of axillary recurrence.CONCLUSION: This study supports the reliability of lymph node status assessmentusing the SLNB before CNA.Copyright © 2018 Elsevier Masson SAS. All rights reserved.DOI: 10.1016/j.gofs.2018.05.002 PMID: 29776842 